Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase NA 4Phase 4 4Phase 1 3Phase 2/3 2Phase 1/2 1

Status

Completed 3Withdrawn 1Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Hearing Loss 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Completed × Acetylcysteine × Clear all
NCT04887194 2024-05-08

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

Mirati Therapeutics Inc.

Phase 1 Completed
40 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT02094625 2023-04-18

NAC to Prevent Cisplatin-induced Hearing Loss

Children's Hospital Los Angeles

Phase 1 Completed
52 enrolled
GastrointestinalSarcoma

Liver Neoplasms, Osteosarcoma, Neuroectodermal Tumors, Primitive, Hearing Loss

NCT02908750 2022-11-14

Study to Assess the Effect of Osimertinib (TAGRISSOâ„¢ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC

AstraZeneca

Phase 1 Completed
24 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡